COMPANY INFO
Insilico Medicine is a private biotechnology company founded in 2014 by Alex Zhavoronkov. It has approximately 350 employees and is headquartered in Boston, Massachusetts, with additional facilities in Hong Kong and New York. The company operates in the drug discovery industry, leveraging artificial intelligence, deep learning, and big data analysis to develop novel drugs and therapeutic solutions targeting cancer, fibrosis, immunity, central nervous system diseases, and age-related conditions. Insilico Medicine's AI-driven platform accelerates drug discovery by combining genomics and machine learning to reduce the time and cost of bringing new medications to market. Its official website is insilico.com.
Insilico Medicine is a biotechnology company leveraging artificial intelligence and deep learning to accelerate drug discovery, focusing on therapeutic solutions for cancer, fibrosis, immunity, central nervous system diseases, and age-related conditions. Headquartered in Boston with operations in Hong Kong and New York, Insilico Medicine integrates cutting-edge genomics and machine learning to reduce the time and cost of bringing novel medications to market.
Insilico Medicine executives bring together expertise in AI, computational biology, drug development, and global business strategy. The Insilico Medicine leadership team is defined by scientific excellence, deep industry experience, and a commitment to revolutionizing drug discovery with artificial intelligence. The management team’s accomplishments span major pharmaceutical innovations, high-impact academic research, and high-profile partnership building, all driving the company’s ongoing success and rapid growth in the biotech industry.
As Founder and CEO, Alex Zhavoronkov leads Insilico Medicine’s strategic direction, overseeing the integration of AI technologies for drug discovery and driving the company’s expansion into clinical-stage development of therapeutics targeting aging-related diseases, cancer, fibrosis, and immunity. Under Alex Zhavoronkov’s leadership, Insilico Medicine has launched multiple AI-driven platforms, secured over $100 million in funding, and forged significant partnerships with major pharmaceutical companies, living up to the company founder’s vision for AI-powered healthcare.
Dr. Zhavoronkov holds a PhD in Molecular Biology from Columbia University and conducted postdoctoral research at Cambridge University. Before founding Insilico Medicine in 2014, he co-founded PharmaVision and served as Chief Technology Officer at Biotica Technology. He is a prolific author in AI and longevity research, holding multiple patents and publishing over 100 peer-reviewed articles, which have cemented his role as one of the most influential leaders in AI-driven biotechnology.
As Co-Founder & President, Alex Aliper drives global business operations for Insilico Medicine, orchestrating strategic initiatives across North America, Europe, and the UAE. Alex Aliper spearheads partnerships in aging research and clinical trials, expanding Insilico Medicine’s portfolio of AI-enabled drug discovery projects and fostering strong academic and industry collaborations that reinforce the company’s leadership in innovative therapeutics.
Alex Aliper holds a PhD in Neuroscience from the University of Toronto. He previously led translational research teams at Merck and co-founded a biotech startup focused on neurodegenerative diseases. A published authority on AI applications in neurobiology, Alex Aliper also contributes to scientific advisory boards in the aging research community, further strengthening Insilico Medicine’s executive ranks.
As CSO and Co-CEO, Dr. Feng Ren directs Insilico Medicine’s scientific research strategy, guiding the development of deep generative models and reinforcement learning pipelines for novel target discovery. Dr. Feng Ren co-leads the executive team, ensuring scientific innovation is efficiently integrated into Insilico Medicine’s product pipelines and sustaining the company’s competitive edge in biotech AI.
Dr. Ren earned his PhD in Computational Biology from Peking University and previously spent seven years as a research scientist at Merck’s AI division. Joining Insilico Medicine in 2016, his expertise in structural bioinformatics and AI-driven chemogenomics has resulted in several high-impact publications and patented methodologies, making him pivotal in shaping the company’s research capabilities.
As Chief Medical Officer, Dr. Sujata Rao oversees clinical development and regulatory strategy, leading the design and execution of trials for Insilico Medicine’s AI-discovered drug candidates. Dr. Rao manages medical affairs and liaises with health authorities, ensuring innovative therapeutics progress efficiently through the approval pipeline.
Dr. Rao holds an MD from AIIMS, India, and an MPH from Harvard T.H. Chan School of Public Health. Previously Vice President of Medical Affairs at Novartis Oncology, she has guided numerous NDA submissions and driven clinical programs for targeted therapies, bringing over 15 years of experience in clinical development and pharmacovigilance to the Insilico Medicine management team.
As Chief Business Officer, Michelle Chen leads corporate strategy, business development, mergers & acquisitions, and global fundraising efforts at Insilico Medicine. Michelle Chen shapes the product portfolio, directs strategic partnerships, and spearheads licensing deals, enabling the scale and reach of Insilico Medicine’s AI-driven drug discovery platforms and solidifying the company’s foundation for sustainable growth.
Michelle Chen holds a PhD in Biochemistry from the University of Washington and completed post-doctoral research at UCSF. With over 20 years' experience at Merck, Roche, and BioMarin, she has negotiated major licensing agreements and built corporate development teams, making her a critical executive in Insilico Medicine’s leadership structure.
As General Manager of Insilico Medicine US, Qingsong Zhu handles US operations and leads integration of AI platforms with biomarker development teams. Qingsong Zhu has optimized R&D workflows, accelerating the preclinical validation of AI-identified targets, and has expanded Insilico Medicine’s US biotech partnerships.
Dr. Zhu earned his PhD in Biochemistry from Kansas State University and conducted cancer epigenetics research at Johns Hopkins University. He previously served as COO of Insilico Medicine from 2014 to 2021, where he was instrumental in managing product development teams and platform engineering, enhancing the company’s operational efficiency.
As CEO of Insilico Medicine Taiwan, Jimmy Lin leads business development and R&D in the APAC region, establishing AI-driven collaborations with pharmaceutical companies. Jimmy Lin has grown the Taiwan office into a regional hub for compound screening and algorithm development, solidifying Insilico Medicine’s international executive team.
Jimmy Lin holds a PhD in Pharmaceutical Sciences from ETH Zurich and boasts extensive experience in computational chemistry, leading peptide design research at A*STAR and Harvard before founding Insilico Taiwan in 2019. His scientific and business acumen contributes to the global reach of Insilico Medicine’s management team.
Keith Mikule heads business development and alliance management for oncology and immunology projects, negotiating licensing agreements and managing strategic co-development collaborations. Keith Mikule advances Insilico Medicine's portfolio through partnership governance and alliance execution.
He holds a PhD in Cell and Developmental Biology from the University of Colorado. Before joining Insilico Medicine, Keith Mikule led pharmacology and strategic alliances at TESARO and was VP Search & Evaluation at Boston Pharmaceuticals, building out high-value drug pipelines and enhancing the company’s business development capabilities.
As VP of Biology & Translational Medicine, Maya Zhang leads the company’s translational research programs, validating AI-identified targets in preclinical models and accelerating biomarker discovery to support clinical development. Maya Zhang is a key Insilico Medicine executive responsible for advancing oncology and chronic disease programs.
Dr. Zhang received her PhD in Pharmacology from The University of Texas at Austin. She led discovery biology teams at Denovo Pharmatech and Sinovant, bringing several IND filings and translational programs in HBV and oncology to fruition, adding significant value to Insilico Medicine’s scientific leadership.
The Insilico Medicine leadership team is comprised of accomplished executives and scientific leaders whose expertise in artificial intelligence, pharmaceutical R&D, translational medicine, and global business development underpins the company’s reputation as a pioneer in AI-powered drug discovery. Under the guidance of the CEO, president, and co-CEOs, Insilico Medicine’s management structure emphasizes cross-functional collaboration between science, business, and clinical teams, ensuring that innovations in AI quickly translate into tangible therapeutic solutions.
Websets is a powerful natural language search and data enrichment tool that helps you research executive teams for any company. Whether you're analyzing the Insilico Medicine leadership team or exploring management structures at other organizations, Websets provides comprehensive insights into executive backgrounds, roles, and team dynamics.
With Websets, you can access detailed executive team profiles, management structures, and leadership insights through intuitive natural language queries. Sign up now to enhance your executive team research capabilities.